Nivolumab + ipilimumab (mesothelioma)
Checked 2026-09-09
Unresectable pleural mesothelioma first line, especially non-epithelioid
One cycle
every 42 daysComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Nivolumab Monoclonal antibody (anti-PD-1) | 360 mg every 3 weeks | IV | D1, 22 | |
Ipilimumab Monoclonal antibody (anti-CTLA-4) | 1 mg/kg every 6 weeks | IV | D1 |
Cycles
up to 2 years
42-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Used in
Trials
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.